We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Transcutaneous Bilirubin Estimated in ELBW Infants

By LabMedica International staff writers
Posted on 31 Jul 2018
Hyperbilirubinemia is seen in almost two-thirds of term and more than two-thirds of all preterm infants. More...
The incidence of kernicterus has dramatically decreased since the onset of regular screening and aggressive management with phototherapy (PHT).

Transcutaneous bilirubinometry (TcB) is a quick, painless and reliable alternative to serum bilirubin measurements in the management of hyperbilirubinemia. Following PHT, TcB measurements are considered unreliable, as PHT causes bleaching of the skin.

Pediatricians at the Lucile Salter Packard Children’s Hospital (Palo Alto, CA, USA) and their colleagues enrolled a population that consisted of extremely low birth weight (ELBW) infants born at University of Texas Medical Branch (UTMB, Galveston, TX, USA) receiving phototherapy for hyperbilirubinemia. ELBW infants were defined as infants with a birth weight of less than 1,000 g. A total of 19 infants were enrolled in the study, with a mean gestational age of 26 ± 2 weeks and mean weight 827 ± 127 g.

Prior to starting PHT, an opaque patch was placed on the back of the infant. PHT was started by using a Giraffe Blue Lite PT system and continued for five days. Transcutaneous bilirubin in covered area (TcB-C), and exposed area (TcB-E) and total serum bilirubin (TSB) levels were obtained at birth and every 24 hours for five days. TcB measurements were obtained using the Respironics BiliCheck noninvasive bilirubin meter. Serum bilirubin levels (TSB) were used as the gold standard.

The scientists found that the difference between TcB-C and TSB was 2.68 ± 2.41 mg/dL (mean ± SD), which was significantly different statistically. In contrast, the difference between TcB-E and TSB was − 0.51 ± 1.74 mg/dL, which was also statistically significant. TcB-C consistently overestimates TSB, while TcB-E consistently underestimates TSB. The authors concluded that during PHT exposure, TcB-C does not correlate with TSB values in ELBW infants and that TcB-C levels cannot be used as a surrogate for TSB measurement in ELBW infants. The study was published on July 10, 2018, in the journal BMC Pediatrics.



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Silver Member
PCR Plates
Diamond Shell PCR Plates
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.